Study sizes are frequently small, endpoints vary, and results are inconsistent across routes of administration
Understanding this evolving research area is important for clinicians managing patients with both metabolic conditions and substance use history
With ongoing trials and results expected in 2026, Retatrutide could see an official release by 2028
Under the supervision of a Houston doctor, these targeted medications interact with your brain to signal fullness, slow digestion, and quiet the food noise. By addressing the root chemical imbalances of insulin resistance and hunger, GLP-1 medications level the playing field
10.1111/imr.12137 Immunol
As in previous trial results, the drug was also linked with lower LDL cholesterol, triglycerides, systolic blood pressure and triglycerides